Anti-Infective Vaccines Market have been Prophesied to Grow at a Faster Pace by 2026.
Rapidly spreading infectious diseases such as tuberculosis, malaria, Hepatitis B, HIV/AIDS, influenza and others are becoming major concern to the society and the healthcare professionals as they are majorly contributing to worldwide causes of death and presenting huge burden on healthcare systems. Infectious diseases are treated with category of drugs including antivirals and anti-infective agents along with adjunct therapy of immune system boosters.
Anti-infective vaccines are the most powerful health measure taken by the healthcare systems to prevent the rapidly spreading infectious diseases. Infectious diseases being a substantial health threat, numerous companies are trying to innovate novel anti-infective vaccines to combat patient burden on medical managements. Anti-infective vaccines for the prophylaxis of diseases such as influenza (Fluarix, Fluzone, FluMist), hepatitis (Recombivax HB, Havrix, Engerix-B), malaria (RTS,S), polio (IPOL), tuberculosis (BCG) are readily available in market. Anti- infective vaccines for some infectious diseases such as polio and tetanus are given to child after birth under the national immunization programs.
Anti-infective vaccines Market: Drivers and Restraints
Increasing incidence of infectious diseases, incidence of new emerging diseases, bioterrorism and resistance to existing anti-infective therapies are the major drivers for the growth of global anti-infective vaccines market. Moreover, growing awareness for infectious disease diagnosis, increasing health consciousness, advancements in medical technology, thriving demands for control on infectious diseases are some other factors expected to flourish the growth of global anti-infective vaccines market. However, unavailability of anti-infective vaccines in some underdeveloped regions and high prizes of immunization can be the hurdles in the growth of global anti-infective vaccines market.
Anti-infective vaccines Market: Segmentation
The global anti-infective vaccines market has been segmented on the basis of product type, disease type end users and geography.
Based on product type, the global anti-infective vaccines market is segmented into following:
DNA & recombinant vector Vaccines
Others (subunit, conjugate, toxoid vaccines)
Based on disease type, the global anti-infective vaccines market is segmented into following:
Tetanus & Diphtheria Vaccines
Others (anthrax, plague etc.)
Others (rabies, zoster etc.)
Based on the distribution channel, the global anti-infective vaccines market is segmentedinto the following:
Retail Pharmacies and Drug Stores
Anti-infective vaccines Market: Overview
The global anti-infective vaccines market possesses a high growth potential owing to ongoing researches and studies by government as well as research institutes for the development of prophylactic vaccines for various infectious diseases. Market for viral diseases vaccines is likely to hold major share in global anti-infective vaccines market due to threat of treating the disease. Government vaccination centers end user segment majorly contributes to the global anti-infective vaccines market volume due to strong patient pool towards national immunization programs.
Anti-infective vaccines Market: Regional Wise Outlook
Geographically, the global anti-infective vaccines market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America anti-infective vaccines market is estimated to lead the global anti-infective vaccines market due to existence of highly planned healthcare reimbursement schemes and higher purchasing power for expensive vaccines. Additionally, APAC and MEA anti-infective vaccines market are expected to grow rapidly during the forecast period because of rising national healthcare expenditure and urge to prevent the spread of infectious diseases
Anti-infective vaccines Market: Key Players
Some of the major players in the global anti-infective vaccines market are Barr Labs, Inc., Emergent BioDefense Operations Lansing Inc., Organon Teknika Corp LLC, Sanofi Pasteur, Inc., GlaxoSmithKline Biologicals, Merck & Co, Inc., CSL Limited, MedImmune LLC, ID Biomedical Corp., Novartis Vaccines and Diagnostics Limited, Protein Sciences Corporation, Intercell Biomedical, Wyeth Pharmaceuticals, Inc., MassBiologics, Berna Biotech, Ltd. and others. Numerous companies such as GlaxoSmithKline Pharmaceuticals Ltd., VaxGen etc. are engaged in the development of HIV vaccines which are expected to launch in near future.
Source: fortune enterpriser